Publications

Detailed Information

Efficacy of Intranasal Administration of the Recombinant Endolysin SAL200 in a Lethal Murine Staphylococcus aureus Pneumonia Model

DC Field Value Language
dc.contributor.authorBae, Ji Yun-
dc.contributor.authorJun, Kang Il-
dc.contributor.authorKang, Chang Kyung-
dc.contributor.authorSong, Kyoung-Ho-
dc.contributor.authorChoe, Pyoeng Gyun-
dc.contributor.authorBang, Ji-Hwan-
dc.contributor.authorKim, Eu Suk-
dc.contributor.authorPark, Sang Won-
dc.contributor.authorKim, Hong Bin-
dc.contributor.authorKim, Nam-Joong-
dc.contributor.authorPark, Wan Beom-
dc.contributor.authorOh, Myoung-don-
dc.date.accessioned2024-04-26T01:03:01Z-
dc.date.available2024-04-26T01:03:01Z-
dc.date.created2020-01-30-
dc.date.issued2019-04-
dc.identifier.citationAntimicrobial Agents and Chemotherapy, Vol.63 No.4, p. e02009-18-
dc.identifier.issn0066-4804-
dc.identifier.urihttps://hdl.handle.net/10371/199647-
dc.description.abstractSAL200 is derived from a phage endolysin and is a novel candidate drug for the treatment of Staphylococcus aureus infection. We investigated the efficacy of the recombinant endolysin SAL200 in a lethal murine pneumonia model. Lethal pneumonia was established by intranasally administering a methicillin-susceptible (Newman) or methicillin-resistant (LAC) S. aureus strain into BALB/c mice. The mice were treated with a single intranasal administration of SAL200 or phosphate-buffered saline at 2 h after S. aureus infection. The survival rates were recorded until 60 h after the bacterial challenge. The bacterial loads in the lungs and blood, histopathology of lung tissues, and serum cytokine levels were evaluated following the S. aureus challenge. The SAL200-treated group and control group exhibited 90% to 95% and 10% to 40% survival rates, respectively. The bacterial loads in the lungs of the SAL200-treated group were significantly lower by similar to 10-fold than those of the control group as early as 1 h after treatment. Histopathologic recovery of pneumonia was observed in the SAL200-treated mice. The cytokine levels were comparable between groups. These results suggest that direct administration of SAL200 into the lungs could be a potential adjunct treatment against severe pneumonia caused by S. aureus.-
dc.language영어-
dc.publisherAmerican Society for Microbiology-
dc.titleEfficacy of Intranasal Administration of the Recombinant Endolysin SAL200 in a Lethal Murine Staphylococcus aureus Pneumonia Model-
dc.typeArticle-
dc.identifier.doi10.1128/AAC.02009-18-
dc.citation.journaltitleAntimicrobial Agents and Chemotherapy-
dc.identifier.wosid000462474100025-
dc.identifier.scopusid2-s2.0-85063663182-
dc.citation.number4-
dc.citation.startpagee02009-18-
dc.citation.volume63-
dc.description.isOpenAccessY-
dc.contributor.affiliatedAuthorKim, Eu Suk-
dc.contributor.affiliatedAuthorPark, Sang Won-
dc.contributor.affiliatedAuthorKim, Hong Bin-
dc.contributor.affiliatedAuthorKim, Nam-Joong-
dc.contributor.affiliatedAuthorPark, Wan Beom-
dc.contributor.affiliatedAuthorOh, Myoung-don-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.subject.keywordPlusBACTERIOPHAGE ENDOLYSINS-
dc.subject.keywordPlusPHAGE ENDOLYSIN-
dc.subject.keywordPlusRELEASE-
dc.subject.keywordPlusCPL-1-
dc.subject.keywordPlusLYSIN-
dc.subject.keywordPlusMICE-
dc.subject.keywordAuthorSAL200-
dc.subject.keywordAuthorStaphylococcus aureus-
dc.subject.keywordAuthormice-
dc.subject.keywordAuthorphage endolysin-
dc.subject.keywordAuthorpneumonia-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Related Researcher

  • College of Medicine
  • Department of Medicine
Research Area Immunology, Infectious Diseases, Vaccination, 감염병, 바이러스질환, 예방접종

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share